|
Chairman and Chief Executive Officer
Nutra Pharma Corporation
Rik J. Deitsch has been the President,
Chief Executive Officer and a Director of
the Company since November 7, 2002. From
February 1998 through November 2002, Mr.
Deitsch served as the President of NDA Consulting
Inc., a biotechnology research group that
provided consulting services to the pharmaceutical
industry. NDA Consulting specialized in
the research of peptides derived from Cone
Snail venom, Cobra venom and Gila Monster
venom. Mr. Deitsch holds both a B.S. in
Chemistry and an M.S. in Biochemistry from
Florida Atlantic University and has conducted
clinical and laboratory research in collaboration
with scientists at Duke University Medical
Center and the Cleveland Clinic . Mr. Deitsch
is an adjunct professor and teaches several
courses for Florida Atlantic University's
College of Business and Continuing Education
Department. |
| |
|
| |
|
|
Chief Executive Officer
ReceptoPharm, Inc.
Paul F. Reid, Ph.D., is a Co-Founder and
Chief Executive Officer of ReceptoPharm.
Dr. Reid is equipped with a broad scientific
background, encompassing 14+ years in clinical
development and research, with a direct
approach to moving products from preclinical
into clinical phases. He has worked and
negotiated with drug regulatory agencies
in the US, Canada, EU, South America, South
Africa, and China, enabling companies to
move ahead, save millions on research and
testing in clinical trials, and gain IND
approvals. By leveraging his comprehensive
understanding of regulatory requirements
he can guide new projects through the correct
protocols at a minimum budget, advancing
products, positioning for licensing, and
setting up manufacturing. The application
of his knowledge of laboratory practices
to select new technologies that enhance
production, quality control, and product
formats. Dr. Reid is a leading world expert
in the therapeutic use of snake venom neurotoxins.
|
| |
|
| |
|
|
President
ReceptoPharm, Inc.
Harold H. Rumph has been President and
Director of the Company since March of 2003
and bring with him a career devoted to technical
sales and marketing. From 1988 to 2003 he
was founder and owner of a high tech business
providing computerized scheduling services
to the construction industry. From 1986
to 1988, Mr. Rumph was Director of Sales
and Marketing for JE Research, Inc. From
1980 to 1986 he was a founder, President,
and Director of Biogenix, Inc. This company
was involved in the development, manufacturing,
and marketing of in-hospital bedside and
ambulatory Patient Monitoring Systems. Biogenix
was also involved with research and development
of antiviral peptides from cobra venoms,
including clinical trials under FDA-issued
Investigational New Drug applications. Prior
to the above Mr. Rumph led sales teams and
was responsible for marketing at Harris
Communications, Harris Computers, Memorex
Corporation, Xerox Corporation, Cincinnati
Milacron, Amdahl Corporation, RCA Computers,
and IBM. Mr. Rumph received his BS degree
from the United States Naval Academy. |
| |
|
| |
|
| |
Director
Dr. Lonky is board certified in internal
medicine, pulmonary and critical care medicine.
As a National Institutes of Health post
doctoral fellow and faculty member at the
University of California, San Diego, he
spearheaded a research team studying the
cellular and biochemical mechanisms of lung
injury. He has published over a dozen articles
in the peer-reviewed literature in this
field. His practice involves the evaluation
and treatment of patients with toxic exposures
as well as patients with lung disease, and
he has co-authored the book Invisible Killers,
The truth about environmental genocide.
From 1990-2006 he served as Chief Medical
Officer of a medical device company that
developed diagnostic products for the early
diagnosis of cervical and oral cancer. In
that role, his duties included the direction
of clinical research and the ultimate clearance
of three new diagnostic devices by the U.S.
Food and Drug Administration (FDA). Dr.
Lonky has published numerous articles in
the peer-reviewed literature in the area
of cellular physiology and its relation
to cervical and oral cancer detection. Since
Early 2007 he has been a Board Member of
Histologix, LLC, a company that is bringing
innovative biopsy tools to the medical marketplace.
Dr. Lonky is specifically involved with
the regulatory clearances of these novel
devices for use on various tissue surfaces.
Dr. Lonky earned his B.S. degree at St.
Lawrence University, his M.D. from the State
University of New York, Downstate, and his
M.B.A. from Pepperdine University.
|
| |
|
| |
|
| |
Director
Stanley J. Cherelstein is currently the
CEO and President of Waiora, a company that
develops and distributes Healthy Aging products.
Mr. Cherelstein was the past President and
Chief Operating Officer of Unicity, Inc.,
a $300 million nutritional supplement company
with offices in thirteen countries in North
America, Asia and Europe. Prior to serving
as President, he was the Chief Operating
Officer of Unicity where he was responsible
for global operations including supply chain,
distribution, information technology, customer
service, human resources and finance. From
May 1999 to June 2002 Mr. Cherelstein served
as the Senior Vice President of Finance
and Operations at Rexall Showcase International
(RSI), a division of Rexall Sundown. RSI
was a $180 million nutritional supplement
company that operated in the USA, Japan,
Korea, Taiwan and Hong Kong. Mr. Cherelstein
began his career in public accounting at
the firm of Cooper's and Lybrand where he
worked for a total of five years including
three years in auditing and two years in
management consulting. After public accounting
he worked as a Corporate Controller for
six years in the wholesale distribution
and retail industries. Mr. Cherelstein is
a graduate of the University of Pittsburgh
where he obtained a B.S. in Business and
Accounting. |
|
|
| |
|
|
|
| |
|
| Click
Here for an Update on the Phase IIb Clinical Trial
Data. |
|
|
|
|
| |
|